Effect of Proton Pump Inhibitors (PPI) and H2 Receptor Antagonists (H2RA) on Response to Therapy with Fidaxomicin or Vancomycin in Hospitalized Patients with Clostridium difficile Infection

Effect of Proton Pump Inhibitors (PPI) and H2 Receptor Antagonists (H2RA) on Response to Therapy with Fidaxomicin or Vancomycin in Hospitalized Patients with Clostridium difficile Infection

Bibliographic Details
Main Authors:	Weiss, K, Louie, T, Miller, M, Mullane, K, Crook, D, Esposito, R, Gorbach, S
Format:	Conference item
Published:	2011

Similar Items

Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
by: Thomas Louie, et al.
Published: (2015-12-01)

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
by: Cornely, O, et al.
Published: (2012)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
by: Christine Lee, et al.
Published: (2016-01-01)

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
by: Crook, D, et al.
Published: (2012)

Factors Influencing Time to Resolution of Diarrhea in Patients with Clostridium difficile Infection Treated with Fidaxomicin or Vancomycin.
by: Gerding, D, et al.
Published: (2012)

Clostridium difficile in 7 European countries and North America: Fidaxomicin vs vancomycin therapy
by: Crook, D, et al.
Published: (2012)

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
by: Cornely, O, et al.
Published: (2012)

Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile
by: Eyre, D, et al.
Published: (2013)

Clinical and Economic Consequences of Vancomycin and Fidaxomicin for the Treatment of Clostridium difficile Infection in Canada
by: Monika Wagner, et al.
Published: (2014-01-01)

Proteomic Signatures of <i>Clostridium difficile</i> Stressed with Metronidazole, Vancomycin, or Fidaxomicin
by: Sandra Maaß, et al.
Published: (2018-11-01)

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
by: Sears, P, et al.
Published: (2012)

Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection
by: George G Zhanel, et al.
Published: (2015-01-01)

Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.
by: Mullane, K, et al.
Published: (2013)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
by: A. Krishna Rao, et al.
Published: (2022-07-01)

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
by: Anke van Engen, et al.
Published: (2015-05-01)

Does Fidaxomicin reduce Cure and Recurrence rates compared to Vancomycin in Clostridium Difficile Infection patients?: A Systematic Review and Meta-analysis
by: Hiral N Golakiya, et al.
Published: (2022-06-01)

Effect of age on treatment outcomes in Clostridium difficile infection.
by: Louie, T, et al.
Published: (2013)

Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile Infection.
by: Louie, T, et al.
Published: (2011)

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study
by: Marcos Hernando-Gozalo, et al.
Published: (2024-05-01)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
by: Oliver MB, et al.
Published: (2022-09-01)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
by: Laura Whitney, et al.
Published: (2023-01-01)

The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
by: Ronald G. Hall, et al.
Published: (2022-02-01)

In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats
by: Sergio Álvarez-Pérez, et al.
Published: (2023-11-01)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
by: Dominador Lao, et al.
Published: (2012-01-01)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
by: George Tannous, et al.
Published: (2010-09-01)

Association Between Risk of Clostridium difficile Infection and Duration of Proton Pump Inhibitor or H2-Receptor Antagonist Use in Hospitalized Patients
by: Chien-Huei Huang, et al.
Published: (2024-01-01)

Toxic megacolon associated with Clostridium difficile infection recurrence: a case report complicated by multiple bacterial infections and successfully treated with oral fidaxomicin
by: Addolorata Masiello, et al.
Published: (2014-12-01)

Real-world effectiveness of fidaxomicin in patients at high risk of Clostridioides difficile recurrence
by: Benjamin Colwell, et al.
Published: (2024-01-01)

Clostridium difficile associated diarrhea, successfully managed with custom prepared oral vancomycin
by: JAMA Jayatilake, et al.
Published: (2022-04-01)

Nature’s Therapy for Recurrent Clostridium Difficile Diarrhea
by: Thomas Louie, et al.
Published: (2008-01-01)

Clostridium difficile mixed infection and reinfection.
by: Eyre, D, et al.
Published: (2012)

Vancomycin-Resistant Enterococcus faecium Colonization and Clostridium difficile Infection in a Hematologic Patient
by: Ivana Goić-Barišić, et al.
Published: (2020-01-01)

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD
by: L. Walsh, et al.
Published: (2024-12-01)

Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection.
by: Stoesser, N, et al.
Published: (2011)

Multilocus sequence typing of Clostridium difficile.
by: Griffiths, D, et al.
Published: (2010)

Caring at the transition: success and financial barriers of fidaxomicin discharge prescriptions for inpatients with Clostridioides difficile infection
by: Ellen Earle, et al.
Published: (2025-01-01)

Clostridium difficile
by: Emily Macnaughton
Published: (2014-05-01)

Clostridium Difficile
by: Sushil Adhikari
Published: (2018-06-01)

The Complexity and Diversity of the Pathogenicity Locus in Clostridium difficile Clade 5.
by: Elliott, B, et al.
Published: (2014)

Evolutionary history of the Clostridium difficile pathogenicity locus.
by: Dingle, K, et al.
Published: (2014)